Straight to the point—

Exclusive microneedle delivery system redefines the vaccine experience

Helps protect against 2 A and 2 B influenza strains

Order today for patients 18 through 64 years of age.

*Fluzone* intradermal QUADRIVALENT INFLUENZA VACCINE

Small. Simple. Smart.

Please [click here](#) for Important Safety Information.
Benefits of intradermal administration

Designed to simplify vaccine administration

Microneedle delivery system
- Delivers an accurate dose of antigen into the dermal layer regardless of a patient’s race, gender, or weight
- Simplifies the administration process because you don’t need to choose among different needle sizes

Please click here for Important Safety Information.

Designed to have fewer steps

Prefilled
- Saves time because there is no need to draw vaccine and no air purging required
- Minimizes the likelihood of making a dosing error

Affixed microneedle
- Simplifies preparation because there is no need to attach needle

Designed with your needs in mind

Integrated needle shield
- Completely covers the needle when activated

90% smaller needle (1.5 mm microneedle)
- Reduces the possibility of damage to nerves and blood vessels

CPT® Code: 90630

* CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.
Intradermal injection—works by utilizing the skin\textsuperscript{1, b}

\begin{itemize}
  \item The skin, rich in dendritic cells, is the body’s first line of defense against infection\textsuperscript{3, 5}
  \item Dendritic cells capture antigens and activate a robust immune response\textsuperscript{3}
\end{itemize}

\textsuperscript{1} A study investigating skin thickness at usual areas for intradermal vaccination found that the mean skin thickness at the deltoid was between 1.9 mm and 2.4 mm.\textsuperscript{6}

\textsuperscript{b} A study investigating skin thickness at usual areas for intradermal vaccination found that the mean skin thickness at the deltoid was between 1.9 mm and 2.4 mm.\textsuperscript{6}

Injection-site expectations

Because immune response occurs under the surface of the skin, redness and swelling at the injection site can be expected.\textsuperscript{1} Reactions usually resolve in 3 to 7 days.\textsuperscript{7}

Illustrations are for visual reference only. Injection-site reactions can vary for each patient.

Visit [Fluzone.com—support beyond immunization.](http://Fluzone.com)

See administration video.

Scan with your smartphone to see the microneedle in action or go to [Fluzone.com/ID](http://Fluzone.com/ID)

Please [click here](http://Fluzone.com/ID) for Important Safety Information.
Fluzone Intradermal Quadrivalent vaccine—safety profile

Frequency of solicited injection-site reactions and systemic adverse events (AEs) within 7 days post-vaccination¹

Please see full Prescribing Information for additional safety data, including rates of solicited AEs by intensity category.

<table>
<thead>
<tr>
<th>Injection-site adverse reactions</th>
<th>Fluzone Intradermal Quadrivalent Vaccine (N=1649-1656)</th>
<th>TIV-ID¹d (B Yamagata) (N=819-820)</th>
<th>TIV-ID²e (B Victoria) (N=836-838)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain</td>
<td>53%</td>
<td>48%</td>
<td>50%</td>
</tr>
<tr>
<td>Pruritus</td>
<td>52%</td>
<td>45%</td>
<td>45%</td>
</tr>
<tr>
<td>Erythema</td>
<td>37%</td>
<td>34%</td>
<td>32%</td>
</tr>
<tr>
<td>Swelling</td>
<td>20%</td>
<td>15%</td>
<td>15%</td>
</tr>
<tr>
<td>Induration</td>
<td>17%</td>
<td>14%</td>
<td>11%</td>
</tr>
<tr>
<td>Ecchymosis</td>
<td>3%</td>
<td>2%</td>
<td>2%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Systemic adverse reactions</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Myalgia</td>
<td>34%</td>
<td>29%</td>
<td>31%</td>
</tr>
<tr>
<td>Headache</td>
<td>33%</td>
<td>31%</td>
<td>33%</td>
</tr>
<tr>
<td>Malaise</td>
<td>28%</td>
<td>26%</td>
<td>30%</td>
</tr>
<tr>
<td>Shivering</td>
<td>12%</td>
<td>10%</td>
<td>11%</td>
</tr>
<tr>
<td>Fever (≥100.4°F)¹</td>
<td>1%</td>
<td>1%</td>
<td>1%</td>
</tr>
</tbody>
</table>

¹ N is the number of vaccinated participants with available data for the events listed.
² TIV-ID: 2012-2013 trivalent Fluzone Intradermal vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), and B/Texas/6/2011 (Yamagata lineage), licensed.
³ TIV-ID: Trivalent Investigational Intradermal vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), and B/Brisbane/60/2008 (Victoria lineage), non-licensed.
⁴ Fever measured by any route.

- Injection-site reactions were more frequent with the intradermal vaccine with the exception of pain, which was similar¹
- Generally, reactions were mild to moderate in intensity and resolved in 3 to 7 days⁷
- Unsolicited adverse reaction profile of Fluzone Intradermal Quadrivalent vaccine was similar to that of Fluzone Intradermal vaccine¹

Reserve for the 2015-2016 influenza season

To order Fluzone Intradermal Quadrivalent vaccine or to learn more about the Fluzone Partners Program, log onto VaccineShoppe.com® or call 1-800-VACCINE (1-800-822-2463).
IMPORTANT SAFETY INFORMATION

INDICATION

Fluzone Intradermal Quadrivalent vaccine is indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.

Fluzone Intradermal Quadrivalent vaccine is approved for use in persons 18 through 64 years of age.

SAFETY INFORMATION

The most common local reactions to Fluzone Intradermal Quadrivalent vaccine include pruritus, erythema, swelling, and induration at the injection site. Such reactions occurred more frequently with trivalent Fluzone Intradermal vaccine than with trivalent Fluzone vaccine. Other adverse reactions to Fluzone Intradermal Quadrivalent vaccine include pain at the injection site; myalgia, headache, and malaise. Other adverse reactions may occur.

Fluzone Intradermal Quadrivalent vaccine should not be administered to anyone with a known hypersensitivity (eg, anaphylaxis) to any vaccine component, including egg protein, or to a previous dose of any influenza vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone Intradermal Quadrivalent vaccine should be based on careful consideration of the potential benefits and risks. Vaccination with Fluzone Intradermal Quadrivalent vaccine may not protect all individuals.

Before administering Fluzone Intradermal Quadrivalent vaccine, please click here for full Prescribing Information.

To order Fluzone Intradermal Quadrivalent vaccine or to learn about the Fluzone Partners Program, please log onto VaccineShoppe.com or call 1-800-VACCINE (1-800-822-2463).